24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
NCT01101841 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 570
Last updated 2015-10-15
Summary
To assess the safety and efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause
Conditions
Interventions
- DRUG
-
Brisdelle (paroxetine mesylate)
Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
- DRUG
-
Placebo capsules
Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
Sponsors & Collaborators
-
Noven Therapeutics
lead INDUSTRY
Principal Investigators
-
Derrick R Havin, MD · North Spokane Women's Clinic Research, Spokane, WA 99207
-
Richard E Hedrick, MD · Hawthorne Medical Research, Inc., Winston-Salem, NC 27103
-
Samuel N Lederman, MD · Altus Research, Lake Worth, FL 33461
-
Larry S Seidman, DO · Philadelphia Clinical Research, LLC, Philadelphia, PA 19114
-
James E Tomblin, MD · Hawthorne Medical Research, Inc., Greensboro, NC 27408
-
Peter A Zedler, MD · Virginia Women's Center, Richmond, VA 23233
-
D S Harnsberger, MD · Chattanooga Medical Research, LLC, Chattanooga, TN 37404
-
John A Hoekstra, MD · National Clinical Research, Inc., Richmond, VA 23294
-
Robin Kroll, MD · Women's Clinical Research Center, Seattle, WA 98105
-
Ashley Tunkle, MD · Anchor Research Center, Naples, FL 34102
-
Matthew Davis, MD · Rochester Clinical Research, Rochester, NY 14609
-
Donna DeSantis, MD · East Valley Family Physicians PLC, Chandler, AZ 85224
-
Steven Drosman · Genesis Center For Clinical Research, San Diego, CA 92103
-
Mildred Farmer, MD · Meridien Research, Brooksville, FL 34601
-
Sandra Hurtado, MD · The Woman's Hospital of Texas Clinical Research Center, Houston, TX 77054
-
Bruce Levine, MD · Phoenix Ob-Gyn Associates, LLC, Moorestown, NJ 08057
-
Tyrone Malloy, MD · Soapstone Center for Clinical Research, Decatur, GA 30034
-
Eric Ross, MD · Apex Research Institute, Santa Ana, CA 92705
-
Cynthia Strout, MD · Coastal Carolina Research Center, Mt. Pleasant, SC 29464
-
Arthur Waldbaum, MD · Downtown Women's Health Care, Denver, CO, 80218
-
Edward Zbella, MD · Women's Medical Research Group, LLC, Clearwater, FL 33759
-
James R Dockery, MD · Montgomery Women's Health Associates, PC, Montgomery, AL 36116
-
Stephen C Blank, MD · Mount Vernon Clinical Research, LLC, Sandy Springs, GA 30328
-
Keith Aqua, MD · Visions Clinical Research, Boynton Beach, FL 33472
-
Saul R Berg, MD · Clinical Trials Research Services, LLC, Pittsburgh, PA 15206
-
Marvin Kalafer, MD · The Clinical Trial Center, LLC, Jenkintown, PA 19046
-
David J Portman, MD · Columbus Center for Women's Health Research, Columbus, Ohio 43213
-
Stephen Swanson, MD · Women's Clinic of Lincoln, PC, Lincoln, NE 68510
-
Joseph Soufer, MD · Chase Medical Research, LLC, Waterbury, CT 06708
-
ShaH R Scott, MD · Clinical Research Associates, Inc., Nashville, TN 37203
-
Mary K Neuffer, MD · SC Clinical Research Center, LLC, Columbia, SC 29201
-
Ronald Ackerman, MD · Comprehensive Clinical Trials, LLC, West Palm Beach, FL 33409
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-03-31
- Primary Completion
- 2011-09-30
- Completion
- 2011-11-30
Countries
- United States
Study Locations
More Related Trials
-
Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women
NCT00030914 ·Status: COMPLETED ·Phase: PHASE3
-
MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women
NCT03291067 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2
NCT04003142 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms
NCT03596762 ·Status: COMPLETED ·Phase: PHASE2
-
Hot Flash as a Marker of Cardiovascular Risk in Recent Postmenopause: Effects of Non-hormonal Treatments
NCT03149419 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
NCT06049797 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause
NCT06385795 ·Status: COMPLETED ·Phase: PHASE2
-
A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)
NCT03192176 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms
NCT02865538 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)
NCT01015677 ·Status: TERMINATED ·Phase: PHASE2
-
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
NCT06186531 ·Status: RECRUITING ·Phase: PHASE2
-
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
NCT00256685 ·Status: COMPLETED ·Phase: PHASE3
-
One Week Clinical Study in Subjects With Menopausal Symptoms
NCT06794021 ·Status: COMPLETED ·Phase: NA
-
Raloxifene and Rimostil for Perimenopause-Related Depression
NCT00030147 ·Status: COMPLETED ·Phase: PHASE4
-
Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)
NCT00535288 ·Status: COMPLETED ·Phase: PHASE3
-
Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations
NCT00184795 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause
NCT04003155 ·Status: COMPLETED ·Phase: PHASE3
-
MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women
NCT00894543 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
NCT02653417 ·Status: TERMINATED ·Phase: PHASE2
-
Study To Investigate Effect Of A New Drug (PF-00446687) In Post-Menopausal Women Who Suffer From Sexual Dysfunction.
NCT00479570 ·Status: COMPLETED ·Phase: PHASE2
-
MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms
NCT01418209 ·Status: COMPLETED ·Phase: NA
-
Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms
NCT03541200 ·Status: COMPLETED ·Phase: PHASE2
-
A Double-Blind Study to Evaluate the Effect of Femarelle® on Menopausal on Vasomotor Symptoms
NCT01063725 ·Status: UNKNOWN ·Phase: NA
-
Study of Progesterone in Treatment of Vasomotor Symptoms
NCT03202186 ·Status: TERMINATED ·Phase: PHASE3
-
Zestra in Women With Mixed Sexual Dysfunction
NCT00118495 ·Status: COMPLETED ·Phase: PHASE3